Mazdutide (Dual Glucagon/GLP-1 Receptor Agonist) – IBI362

Product Overview

Mazdutide is an innovative, once-weekly dual agonist peptide engineered to mimic and enhance the biological activity of oxyntomodulin, an endogenous intestinal hormone. By simultaneously activating both the Glucagon-like Peptide-1 (GLP-1) receptor and the Glucagon receptor (GCGR), Mazdutide offers a multifaceted approach to metabolic regulation. This dual-agonism strategy is designed to drive potent appetite suppression via the GLP-1 receptor, while the glucagon receptor component actively increases total energy expenditure and optimizes hepatic lipid metabolism. It is a premier compound utilized in advanced research for weight management, metabolic homeostasis, and the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Technical Specifications

• Molecular Formula: C207H317N45O65

• Molecular Weight: 4563.06 g/mol

• CAS Number: 2259884-03-0

• Receptor Profile: Balanced Dual Agonist (Glucagon Receptor + GLP-1 Receptor)

Mechanism of Action

Mazdutide employs a sophisticated, synergistic mechanism to restore metabolic balance:

• GLP-1 Receptor Agonism: Stimulates glucose-dependent insulin secretion, suppresses glucagon release, and activates central hypothalamic satiety centers to induce sustained appetite reduction and caloric restriction.

• Glucagon Receptor Agonism (GCGR): Direct activation of hepatic glucagon receptors promotes lipid oxidation, glycogenolysis, and thermogenesis. This elevates the basal metabolic rate and provides a direct, pharmacologic mechanism to mobilize and clear hepatic fat (steatosis).

• Metabolic Reprogramming: Enhances amino acid catabolism, promotes ketogenesis, and stimulates fibroblast growth factor 21 (FGF21) secretion, collectively facilitating a profound shift in whole-body substrate utilization.

• Balanced Homeostasis: The optimized ratio of GLP-1/GCGR activity ensures that the potential hyperglycemic effects of glucagon are effectively neutralized by the insulinotropic and metabolic-suppressive effects of GLP-1, resulting in net improvements in both glycemic control and body composition.

Primary Research Applications

Mazdutide is a critical compound for in vitro and animal model studies investigating:

• Advanced Obesity and Chronic Weight Management Models

• Metabolic Dysfunction-Associated Steatohepatitis (MASH/NAFLD)

• Hepatic Lipid Oxidation and Mitochondrial Bioenergetics

• Insulin Sensitivity Optimization in Type 2 Diabetes Models

• Cardiovascular and Metabolic Syndrome Risk Marker Modification

Storage & Handling

For optimal long-term stability, store unopened vials strictly refrigerated at 36°F to 46°F (2°C to 8°C). Do not freeze. Protect strictly from light. Once reconstituted, ensure the solution remains refrigerated and utilized in accordance with laboratory-validated timelines to maintain the integrity of the dual-agonist structure.

⚠️ Important Disclaimer for Carbon Nova Labs Customers: All information provided is for educational and reference purposes only. Mazdutide is sold strictly for laboratory research use only. This compound is not approved by the FDA for human consumption, therapeutic use, or clinical application. Ensure compliance with all institutional safety protocols and consult qualified professionals before conducting research.